The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Radionova E.E.

Dermatovenerological Dispensary No 15, Health Department of Eastern Administrative District, Moscow

Piruzian A.L.

The Centre for Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences, Moscow

Nevozinskaia Z.A.

Centre of Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences

Mil’dzikhova D.R.

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia, 119071 ,Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia, 119071

Petrunin D.D.

Pervyĭ MGMU im. I.M. Sechenova

Korsunskaia I.M.

Centre of Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences

Inverse psoriasis with genital lesions. Features of the clinic and therapy

Authors:

Radionova E.E., Piruzian A.L., Nevozinskaia Z.A., Mil’dzikhova D.R., Petrunin D.D., Korsunskaia I.M.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2020;19(2): 206‑212

DOI: 10.17116/klinderma202019021206

Read: 77507 times

Download PDF (RU)
Contact the author
Table of contents

INVERSE PSORIASIS WITH GENITAL LESIONS. FEATURES OF THE CLINIC AND THERAPY
INVERSE PSORIASIS WITH GENITAL LESIONS. FEATURES OF THE CLINIC AND THERAPY

To cite this article:

Radionova EE, Piruzian AL, Nevozinskaia ZA, Mil’dzikhova DR, Petrunin DD, Korsunskaia IM. Inverse psoriasis with genital lesions. Features of the clinic and therapy. Russian Journal of Clinical Dermatology and Venereology. 2020;19(2):206‑212. (In Russ.)
https://doi.org/10.17116/klinderma202019021206

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Historical aspe­cts and prospects of psoriasis treatment. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):284-292
Clinical case of nevoid hype­rkeratosis of the nipple-areola complex. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):537-540
Therapeutic options in patients with neuralgic amyotrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):39-45
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Systemic glucocorticosteroids for dege­nerative back pain: effi­cacy in radi­culopathy and musculoskeletal pain syndrome. Russian Journal of Pain. 2025;(4):54-59
Tolosa—Hunt syndrome. Russian Annals of Ophthalmology. 2025;(6):114-118
Abstract:

The literature review analyzes clinical data regarding epidemiology and the impact on the quality of life of patients with psoriasis with localization of rashes on the genitals, the features of the clinic of this disease, and discusses modern views on its treatment. Genital involvement in the psoriatic process occurs in approximately 63% of patients with psoriasis. Features of localization slightly change the clinical picture of the disease, aggravate the psycho-emotional state of patients and require a different approach to treatment. Although topical glucocorticosteroids (TGCS) remain the first-choice topical treatment, it is clear that their use given the increased risk of adverse drug reactions, is limited. Preference should be given to modern non-halogenated TGCS with a high therapeutic index. The first-line dermatic drugs for long-term therapy are topical calcineurin inhibitors (tacrolimus ointment) and vitamin D analogues (calcipotriol ointment). These drugs are not inferior in effectiveness to TGCS, are devoid of side effects characteristic of steroid hormones, in particular, they do not cause atrophic changes and positively affect the epidermal barrier, which makes them a valuable therapeutic option for the treatment of psoriasis with localization of lesions in the genital area and other areas with thin skin (face, skin folds).

Keywords:

genital psoriasis
topical therapy
calcipotriol
glucocorticosteroids
methylprednisolone aceponate
topical calcineurin inhibitors
tacrolimus

Authors:

Radionova E.E.

Dermatovenerological Dispensary No 15, Health Department of Eastern Administrative District, Moscow

Piruzian A.L.

The Centre for Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences, Moscow

Nevozinskaia Z.A.

Centre of Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences

Mil’dzikhova D.R.

Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia, 119071 ,Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia, 119071

Petrunin D.D.

Pervyĭ MGMU im. I.M. Sechenova

Korsunskaia I.M.

Centre of Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences

Close metadata

References:

  1. Meeuwis KAP, Potts Bleakman A, van de Kerkhof PCM, Dutronc Y, Henneges C, Kornberg LJ, et al. Prevalence of genital psoriasis in patients with psoriasis. J Dermatolog Treat. 2018;29:754-760.
  2. Ryan C, Sadlier M, De Vol E, Patel M, Lloyd AA, Day A, et al. Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. J Am Acad Dermatol. 2015;72:978-983.
  3. Beck KM, Yang EJ, Sanchez IM, Liao W. Treatment of Genital Psoriasis: A Systematic Review. Dermatol Ther (Heidelb). 2018;8:509-525.
  4. Meeuwis KA, de Hullu JA, Massuger LF, et al. Genital psoriasis: a systematic literature review on this hidden skin disease. Acta Derm Venereol. 2011; 91:5-11.
  5. Van de Kerkhof PCM. Clinical Features. In: van de Kerkhof PCM, ed. Textbook of Psoriasis. Oxford: Blackwell Publishing Ltd; 2003.
  6. Stoof TJ, van der Meijden WI. Psoriasis. In: van der Meijden WI, Ter Harmsel WA, eds. Vulvapathologie. Assen: Koninklijke Van Gorcum BV; 2007.
  7. Bunker CB, Neill SM. The genital, perianal and umbilical regions. In: Rook A, Burns T, Breathnach SM, Cox N, Griffiths CE, editors. Rook’s textbook of dermatology. Oxford: Blackwell Publishing; 2004.
  8. Cold CJ, Taylor JR. The prepuce. BJU Int. 1999;83(Suppl 7.1):34-44.
  9. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1-15.
  10. Gupta MA, Gupta AK. Psoriasis and sex: a study of moderately to severely affected patients. Int J Dermatol. 1997;36:259-262.
  11. Abul Maaty AS, Gomaa AH, Mohammed GF, Youssef IM, Eyada MM. Assessment of female sexual function in patients with psoriasis. J Sex Med. 2013;10:1545-1548.
  12. Yang EJ, Beck KM, Sanchez IM, et al. The impact of genital psoriasis on quality of life: a systematic review. Psoriasis (Auckl). 2018;8:41-47.
  13. Cather JC, Ryan C, Meeuwis K, et al. Patients’ perspectives on the impact of genital psoriasis: a qualitative study. Dermatol Ther. 2017;7:447-461.
  14. MacLean AB, Roberts DT, Reid wMN. Review of 1000 women seen at two specially designated vulval clinics. Curr Obstet Gynaecol. 1998;8:159-162.
  15. Fischer G, Spurrett B, Fischer A. The chronically symptoma tic vulva: aetiology and management. Br J Obstet Gynaecol. 1995;102:773-779.
  16. Fischer G, Rogers M. Vulvar disease in children: a clinical audit of 130 cases. Pediatr Dermatol. 2000;17:1-6.
  17. Singh N, Thappa DM, Jaisankar TJ, Habeebullah S. Pattern of non- venereal dermatoses of female external genitalia in South India. Dermatol Online J. 2008;14:1.
  18. Kohn FM. Hautveränderungen des Penis. Differenzieren Sie den Lokalbefund von gereralisierten Erkrankungen! MMwFortschr Med. 2002;144:30-35.
  19. Buechner SA. Common skin disorders of the penis. BJU Int. 2002;90: 498-506.
  20. Goldman BD. Common dermatoses of the male genitalia. Recognition of differences in genital rashes and lesions is essential and attainable. Postgrad Med. 2000;108:89-86.
  21. Van Dijk F, Thio HB, Neumann HAM. Non-oncological and non-infectious diseases of the penis (penile lesions). EAU-EBU Update Series. 2006;4:13-19.
  22. Coldiron BM, Jacobson C. Common penile lesions. Urol Clin North Am. 1988;15:671-685.
  23. Bonnetblanc J-M. Psoriasis. Ann Dermatol Venereol. 2006;46.133:298-299.
  24. Shenenberger Dw. Curbing the psoriasis cascade: Therapies to minimize flares and frustration. Postgrad Med. 2005;117:9-16.
  25. Salim A, Wojnarowska F. Skin diseases affecting the vulva. Curr Obstet Gynaecol. 2002;12:81-89.
  26. Varghese M, Kindel S. Pigmentary disorders and inflammatory lesions of the external genitalia. Urol Clin North Am. 1992;19:111-121.
  27. Fischer GO. Vulval disease in pre-pubertal girls. Australas J Dermatol. 2001; 42:225-234.
  28. Gross G. Dermatologische Befunde an Mamma und Genitale. Gynakologe. 2001;34:940-948.
  29. Porter wM, Bunker CB. The dysfunctional foreskin. Int J STD AIDS. 2001; 12:216-220.
  30. Merola JF, Li T, Li W, et al. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol. 2016;41:486-489.
  31. Omland SH, Gniadecki R. Psoriasis inversa: A separate identity or a variant of psoriasis vulgaris? Clin Dermatol. 2015;33:456-461.
  32. Korotky NG, Kulikova OD, Petrunin DD. A differentiated approach of the combined topical steroids treatment — minimization the risk for unwanted drug reactions. Consilium Medicum. Dermotology. 2009;3:3-6. (In Russ.)
  33. Luger TA. Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. J Eur Acad Dermatol Venereol. 2011;25:251-258.
  34. Elisyutina OG. Modern principles of allergic dermatoses’ topical treatment. Hospital-replacing technologies: Ambulatory surgery. 2014;3-4(55-56):56-59. (In Russ.)
  35. Volkova EN, Lange DA, Rodina YuA, Tarasova MV. The use of methylprednisolone aceponate in the combined treatment of chronic dermatoses: analysis of erroneous applications. Russian Journal of Clinical Dermatology and Venereology = Klinicheskaya dermatologiya i venerologiya. 2010;8(5):97-102. (In Russ.)
  36. Kochergin NG Petrunin DD. The current view on the problem of the choice of medications for external therapy. Russian Journal of Clinical Dermatology and Venereology = Klinicheskaya dermatologiya i venerologiya. 2011;9(6): 84-92. (In Russ.)
  37. Petrunin DD. Pharmacotherapy: Its impact on morphofunctional characteristics of the epidermal barrier. Vestnik dermatologii i venerologii. 2019; 95(1):59-76. (In Russ.)
  38. Carr WW. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Pediatr Drugs. 2013;15:303-310.
  39. Kyllonen H, Remitz A, Mandelin JM, Elg P, Reitamo S. Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol. 2004;150: 1174-1181.
  40. Chittock J, Brown K, Cork MJ, Danby SG. Comparing the effect of a twice-weekly tacrolimus and betamethasone valerate dose on the subclinical epidermal barrier defect in atopic dermatitis. Acta Derm Venereol. 2015; 95:653-658.
  41. Hachem JP, Houben E, Crumrine D, Man MQ, Schurer N, Roelandt T, et al. Serine protease signaling of epidermal permeability barrier homeostasis. J Invest Dermatol. 2006;126:2074-2086.
  42. Dähnhardt-Pfeiffer S, Dähnhardt D, Buchner M, Walter K, Proksch E, Fölster-Holst R. Comparison of effects of tacrolimus ointment and mometasone furoate cream on the epidermal barrier of patients with atopic dermatitis. J Dtsch Dermatol Ges. 2013;11(5):437-443.
  43. Haussler MR, Whitfield GK, Kaneko I, Haussler CA, Hsieh D, Hsieh JC, et al. Molecular mechanisms of vitamin D action. Calcif Tissue Int. 2013; 92(2):77-98.
  44. Gil Á, Plaza-Diaz J, Mesa MD. Vitamin D: Classic and Novel Actions. Ann Nutr Metab. 2018;72(2):87-95.
  45. Segaert S, Shear NH, Chiricozzi A, Thaçi D, Carrascosa JM, Young H, et al. Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy. Dermatol Ther (Heidelb). 2017;7(3):265-279.
  46. Norsgaard H, Kurdykowski S, Descargues P, Gonzalez T, Marstrand T, Dunstl G, Ropke M. Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy. Arch Dermatol Res. 2014;306:719-729.
  47. Khosravi H, Siegel MP, Van Voorhees AS, Merola JF. Treatment of Inverse/Intertriginous Psoriasis: Updated Guidelines from the Medical Board of the National Psoriasis Foundation. J Drugs Dermatol. 2017;16(8):760-766.
  48. Malecic N, Young H. Tacrolimus for the management of psoriasis: clinical utility and place in therapy. Psoriasis (Auckl). 2016;6:153-163.
  49. Brune A, Miller DW, Lin P, Cotrim-Russi D, Paller AS. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol. 2007;24(1):76-80.
  50. Dattola A, Silvestri M, Bennardo L, Del Duca E, Longo C, Bianchi L, Nisticò S. Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review. Dermatol Ther. 2018;31(6):e12728.
  51. Lebwohl M, Freeman AK, Chapman MS, Feldman SR, Hartle JE, Henning A. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol. 2004;51(5):723-730.
  52. Kreuter A, Sommer A, Hyun J, Bräutigam M, Brockmeyer NH, Altmeyer P, Gambichler T. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol. 2006;142(9):1138-1143.
  53. Liao YH, Chiu HC, Tseng YS, Tsai TF. Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol. 2007; 157(5):1005-1012.
  54. Kleyn CE, Woodcock D, Sharpe GR. The efficacy of 0.1% tacrolimus ointment compared with clobetasone butyrate 0.05% ointment in patients with facial, flexural or genital psoriasis. Br J Dermatol. 2005;153:33.
  55. Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clin Dermatol. 2008;26:448-459.
  56. Khosravi H, Siegel MP, Van Voorhees AS, Merola JF. Treatment of Inverse/Intertriginous Psoriasis: Updated Guidelines from the Medical Board of the National Psoriasis Foundation. J Drugs Dermatol. 2017;16:760-766.
  57. Sarma N. Evidence and Suggested Therapeutic Approach in Psoriasis of Difficult-to-treat Areas: Palmoplantar Psoriasis, Nail Psoriasis, Scalp Psoriasis, and Intertriginous Psoriasis. Indian J Dermatol. 2017;62:113-122.
  58. Dubweb GA, Eldebani S, Alhaddar J. Calcipotriol cream in the treatment of flexural psoriasis. Int J Tissue React. 2003;4:127-130.
  59. Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol. 2004; 51:723-730.
  60. Khlebnikova AN. Rational therapy of infected dermatoses. Effektivnaya farmakoterapiya. Dermatovenerologiya i kosmetologiya. 2013;40(3):22-26. (In Russ.)
  61. Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31:e12589.
  62. Tirado-Sanchez A, Ponce-Olivera RM. Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis. Cutis. 2012;90(3):140-144.
  63. Beck KM, Yang EJ, Sanchez IM, Liao W. Treatment of Genital Psoriasis: A Systematic Review. Dermatol Ther (Heidelb). 2018;8:509-525.
  64. Czuczwar P, Stepniak A, Goren A, Wrona W, Paszkowski T, Pawlaczyk M, et al. Genital psoriasis: a hidden multidisciplinary problem — a review of literature. Ginekol Pol. 2016;87:717-721.
  65. Larsabal M, Ly S, Sbidian E, Moyal-Barracco M, Dauendorffer JN, Dupin N, et al. GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. Br J Dermatol. Mar 2019;180(3):647-656. First published: Sept 06, 2018.
  66. Meeuwis KA, van de Kerkhof PC, Massuger LF, de Hullu JA, van Rossum MM. Patients’ experience of psoriasis in the genital area. Dermatology. 2012; 224:271-276.
  67. Ryan C. Genital psoriasis: the failure of dermatologists to identify genital involvement. Br J Dermatol. 2019;180:460-461.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.